{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:45:34Z","timestamp":1782960334319,"version":"3.54.5"},"reference-count":77,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ymthe.2025.03.038","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T16:57:45Z","timestamp":1743094665000},"page":"3257-3269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["DNA-based delivery of G-CSF as a durable and efficacious approach to treat severe chronic neutropenia"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1298-5797","authenticated-orcid":false,"given":"Marek M.","family":"Drozdz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy T.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Sasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debnath","family":"Maji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delcora A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carleigh","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Liberatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.038_bib1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.immuni.2021.06.006","article-title":"The Neutrophil","volume":"54","author":"Burn","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.03.038_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nri3399","article-title":"Neutrophil recruitment and function in health and inflammation","volume":"13","author":"Kolaczkowska","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib3","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.2741\/2853","article-title":"The role of chemokines in neutrophil biology","volume":"13","author":"Kobayashi","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ymthe.2025.03.038_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/shem.2002.31911","article-title":"Neutropenia: Causes and consequences","volume":"39","author":"Boxer","year":"2002","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOH.0000000000000208","article-title":"How I diagnose and treat neutropenia","volume":"23","author":"Dale","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.10255","article-title":"Severe chronic neutropenia: Treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry","volume":"72","author":"Dale","year":"2003","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib7","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3324\/haematol.2014.110288","article-title":"How we diagnose neutropenia in the adult and elderly patient","volume":"99","author":"Palmblad","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ymthe.2025.03.038_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000872","article-title":"The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action","volume":"7","author":"Fioredda","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.ymthe.2025.03.038_bib9","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4049\/jimmunol.1500861","article-title":"G-CSF and GM-CSF in Neutropenia","volume":"195","author":"Mehta","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cytogfr.2014.07.011","article-title":"G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent","volume":"25","author":"Bendall","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2025.03.038_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2567.2008.02950.x","article-title":"Neutrophil mobilization and clearance in the bone marrow","volume":"125","author":"Furze","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2025.03.038_bib12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ncprheum0291","article-title":"Granulocyte colony-stimulating factor and neutrophils--forgotten mediators of inflammatory disease","volume":"2","author":"Eyles","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib13","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1182\/blood.V76.10.1962.1962","article-title":"Levels of serum granulocyte colony-stimulating factor in patients with infections","volume":"76","author":"Kawakami","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.038_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.1994.tb04725.x","article-title":"Endogenous haemopoietic growth factors in neutropenia and infection","volume":"86","author":"Cebon","year":"1994","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib15","doi-asserted-by":"crossref","first-page":"14008","DOI":"10.1016\/S0021-9258(18)77449-8","article-title":"Purification and characterization of the receptor for murine granulocyte colony-stimulating factor","volume":"265","author":"Fukunaga","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.03.038_bib16","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood.V84.6.1737.1737","article-title":"Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization","volume":"84","author":"Lieschke","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.038_bib17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1074-7613(00)80504-X","article-title":"Impaired Production and Increased Apoptosis of Neutrophils in Granulocyte Colony-Stimulating Factor Receptor\u2013Deficient Mice","volume":"5","author":"Liu","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.03.038_bib18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/bjc.1987.295","article-title":"Phase I\/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer","volume":"56","author":"Bronchud","year":"1987","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2025.03.038_bib19","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1056\/NEJM198806023182202","article-title":"Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium","volume":"318","author":"Gabrilove","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.038_bib20","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.seminhematol.2013.06.010","article-title":"Evaluation and Management of Patients With Isolated Neutropenia","volume":"50","author":"Newburger","year":"2013","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.038_bib23","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood.V81.10.2496.2496","article-title":"A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia","volume":"81","author":"Dale","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.038_bib24","first-page":"705","article-title":"Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation","volume":"3","author":"Petros","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.03.038_bib25","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.3390\/ijms20112776","article-title":"A Critical Review of Electroporation as A Plasmid Delivery System in Mouse Skeletal Muscle","volume":"20","author":"Soko\u0142owska","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.03.038_bib26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1749-6632.1999.tb07957.x","article-title":"Dynamics of Membrane Sealing in Transient Electropermeabilization of Skeletal Muscle Membranes","volume":"888","author":"Gowrishankar","year":"1999","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ymthe.2025.03.038_bib27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/j.1460-2075.1982.tb01257.x","article-title":"Gene transfer into mouse lyoma cells by electroporation in high electric fields","volume":"1","author":"Neumann","year":"1982","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2025.03.038_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cyto.2008.03.002","article-title":"Granulocyte colony-stimulating factor: Molecular mechanisms of action during steady state and \u2018emergency\u2019 hematopoiesis","volume":"42","author":"Panopoulos","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.ymthe.2025.03.038_bib29","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood-2002-06-1734","article-title":"Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis","volume":"101","author":"El Ouriaghli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.038_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ajh.10434","article-title":"Proteolytic cleavage of granulocyte colony-stimulating factor and its receptor by neutrophil elastase induces growth inhibition and decreased cell surface expression of the granulocyte colony-stimulating factor receptor","volume":"74","author":"Hunter","year":"2003","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib31","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1479-5876-8-114","article-title":"Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies","volume":"8","author":"Bonanno","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.038_bib33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0022-3476(05)81760-3","article-title":"Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia","volume":"123","author":"Kearns","year":"1993","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2025.03.038_bib34","first-page":"7","article-title":"A systematic literature review of the efficacy, effectiveness, and safety of filgrastim","volume":"26","author":"Dale","year":"2018","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ymthe.2025.03.038_bib35","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2015-03-634493","article-title":"Severe chronic primary neutropenia in adults: report on a series of 108 patients","volume":"126","author":"Sicre de Fontbrune","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.038_bib36","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/bloodadvances.2021005684","article-title":"Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor","volume":"6","author":"Dale","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.038_bib37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jfma.2010.12.003","article-title":"Clinical manifestations and outcomes of pediatric chronic neutropenia","volume":"111","author":"Wan","year":"2012","journal-title":"J. Formos. Med. Assoc. Taiwan Yi Zhi"},{"key":"10.1016\/j.ymthe.2025.03.038_bib38","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1182\/blood.V84.9.2923.2923","article-title":"Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers","volume":"84","author":"Chatta","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.038_bib39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.V88.1.335.335","article-title":"Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans","volume":"88","author":"Price","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.038_bib40","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0301-472X(99)00112-5","article-title":"A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans","volume":"27","author":"Molineux","year":"1999","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib41","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2174\/1381612043452613","article-title":"The Design and Development of Pegfilgrastim (PEG-rmetHuG-CSF, Neulasta\u00ae)","volume":"10","author":"Molineux","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymthe.2025.03.038_bib42","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/toxsci\/42.2.152","article-title":"Short Communication: Renal Tubular Vacuolation in Animals Treated with Polyethylene-Glycol-Conjugated Proteins","volume":"42","author":"Bendele","year":"1998","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ymthe.2025.03.038_bib43","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.038_bib44","article-title":"Research progress on the PEGylation of therapeutic proteins and peptides (TPPs)","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101516","article-title":"G-CSF - A double edge sword in neutrophil mediated immunity","volume":"54","author":"Martin","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.038_bib47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/pharmaceutics16040535","article-title":"Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases","volume":"16","author":"Sussman","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2025.03.038_bib48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2025.03.038_bib49","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.omtn.2023.05.014","article-title":"Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy","volume":"32","author":"Srivastava","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.03.038_bib50","article-title":"Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings","volume":"8","author":"Au","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ymthe.2025.03.038_bib51","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.03.038_bib52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-Associated Virus (AAV) as a Vector for Gene Therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs."},{"key":"10.1016\/j.ymthe.2025.03.038_bib53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"BioDrugs."},{"key":"10.1016\/j.ymthe.2025.03.038_bib54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/bs.adgen.2014.10.006","article-title":"Gene electrotransfer clinical trials","volume":"89","author":"Heller","year":"2015","journal-title":"Adv. Genet."},{"key":"10.1016\/j.ymthe.2025.03.038_bib55","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1067\/mva.2002.123677","article-title":"Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: Preliminary results of a phase I trial","volume":"35","author":"Comerota","year":"2002","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.ymthe.2025.03.038_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamaoncol.2022.5143","article-title":"Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer: A Phase 1 Nonrandomized Clinical Trial","volume":"9","author":"Disis","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib57","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2025.03.038_bib58","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/17425247.2016.1121990","article-title":"Clinical potential of electroporation for gene therapy and DNA vaccine delivery","volume":"13","author":"Lambricht","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2025.03.038_bib59","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.coi.2011.03.008","article-title":"Electroporation delivery of DNA vaccines: prospects for success","volume":"23","author":"Sardesai","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib60","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.gt.3302213","article-title":"Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation","volume":"11","author":"Wang","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.038_bib61","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.4161\/hv.24702","article-title":"Tolerability of intramuscular and intradermal delivery by CELLECTRA(\u00ae) adaptive constant current electroporation device in healthy volunteers","volume":"9","author":"Diehl","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ymthe.2025.03.038_bib62","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41434-022-00343-4","article-title":"Enzymatically amplified linear dbDNATM as a rapid and scalable solution to industrial lentiviral vector manufacturing","volume":"30","author":"Barreira","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.038_bib63","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/22221751.2020.1787108","article-title":"In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies","volume":"9","author":"Andrews","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.ymthe.2025.03.038_bib64","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2017.09.003","article-title":"In Vivo Production of Monoclonal Antibodies by Gene Transfer via Electroporation Protects against Lethal Influenza and Ebola Infections","volume":"7","author":"Andrews","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.038_bib65","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/jgm.534","article-title":"In vivo gene electrotransfer into skeletal muscle: effects of plasmid DNA on the occurrence and extent of muscle damage","volume":"6","author":"Durieux","year":"2004","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymthe.2025.03.038_bib66","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/gt.2011.198","article-title":"Molecular signature of the immune and tissue response to non-coding plasmid DNA in skeletal muscle after electrotransfer","volume":"19","author":"Mann","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.038_bib67","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2199-8-56","article-title":"Gene expression profiles in skeletal muscle after gene electrotransfer","volume":"8","author":"Hojman","year":"2007","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib68","doi-asserted-by":"crossref","first-page":"10235","DOI":"10.1093\/nar\/gkz768","article-title":"Multiple cytosolic DNA sensors bind plasmid DNA after transfection","volume":"47","author":"Semenova","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.03.038_bib69","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1038\/s41590-024-01966-y","article-title":"DNA-sensing pathways in health, autoinflammatory and autoimmune diseases","volume":"25","author":"Dong","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib70","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41576-019-0151-1","article-title":"DNA sensing by the cGAS\u2013STING pathway in health and disease","volume":"20","author":"Motwani","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2025.03.038_bib71","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4049\/jimmunol.1501836","article-title":"A cGAS-Independent STING\/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines","volume":"196","author":"Suschak","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib72","doi-asserted-by":"crossref","first-page":"13623","DOI":"10.18632\/oncotarget.24426","article-title":"Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies","volume":"9","author":"Hollevoet","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2025.03.038_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1017612","article-title":"Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model","volume":"12","author":"Hollevoet","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib74","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1038\/s41467-022-33309-6","article-title":"DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2","volume":"13","author":"Parzych","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.038_bib75","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3390\/pharmaceutics16040547","article-title":"Enhancing In Vivo Electroporation Efficiency through Hyaluronidase: Insights into Plasmid Distribution and Optimization Strategies","volume":"16","author":"Maji","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2025.03.038_bib76","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1189\/jlb.0407247","article-title":"Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice","volume":"83","author":"Daley","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ymthe.2025.03.038_bib77","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/cyto.a.22503","article-title":"Absolute counting of neutrophils in whole blood using flow cytometry","volume":"85","author":"Brunck","year":"2014","journal-title":"Cytometry. A."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:13:48Z","timestamp":1782958428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625002126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1525001625002126"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.038","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA-based delivery of G-CSF as a durable and efficacious approach to treat severe chronic neutropenia","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}